Navigation Links
PhRMA and Epilepsy Foundation Report More Than 400 Medicines in Development to Treat Neurological Disorders
Date:7/13/2015

WASHINGTON, July 13, 2015 /PRNewswire-USNewswire/ -- America's biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer's disease, multiple sclerosis (MS) and Parkinson's disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.

"Researchers have made tremendous advances in understanding how the nervous system works at the molecular and genetic levels which in turn has translated into the development of more effective treatments for neurological disorders," said John J. Castellani, president and chief executive officer, PhRMA. "These developments mean new options and new hope for the millions of patients suffering from these devastating disorders. As an industry, we remain steadfast in our efforts to unlock the mysteries of these diseases and reduce their burden for generations to come."

Medicines in Development for Neurological Disorders
Medicines in Development for Neurological Disorders
Need for New Treatments for Alzheimer's Disease
Need for New Treatments for Alzheimer's Disease

Neurological disorders consist of more than 600 conditions, impacting an estimated 50 million Americans every year. Although some are well known, many are rare disorders that affect a small number of patients who currently have access to few – if any – effective treatments.

The new report, "Medicines in Development for Neurological Disorders," demonstrates how the newest advancements seek to treat the underlying mechanisms of neurological disorders. Examples of treatments currently in development include:

  • A monoclonal antibody that inhibits the activity of calcitonin gene-related peptide (CGRP). Research suggests that CGRP pathways may be involved in the development of migraines and by inhibiting CGRP activity, anti-CGRP antibodies help inhibit the transmission of pain signals associated with migraines.
  • A medicine for Huntington's disease that targets an enzyme, PDE10A, which is present in the neurons most damaged in this inherited disorder that causes a progressive breakdown of nerve cells in the brain.
  • A monoclonal antibody for amyotrophic lateral sclerosis (ALS), which is an inhibitor of the protein Nogo-A that may help keep the motor neurons and muscle fibers connected in hopes that it will lead to a slowing or stopping of disease progression.
  • A monoclonal antibody for relapsing MS, which targets a protein involved in the development of myelin, a protective sheath covering the nerve fibers. This medicine could help restore nerve communication in MS patients.

"As a parent of a child living with epilepsy, I know just how important innovation is to improving the quality of life for individuals living with seizures," said Philip M. Gattone, president and CEO of the Epilepsy Foundation. "Innovative new therapies are particularly important for the one-third of people with epilepsy who don't have their seizures under control, as well as the millions of other Americans living with chronic conditions that cannot be managed by current treatment options."

With 420 medicines in human clinical trials or under review by the Food and Drug Administration (FDA), these new treatments represent a growing understanding of neurological disorders, fueled by both successes and setbacks in research, which will ultimately provide patients and their families with better options.

About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.FromHopetoCures.org
www.Facebook.com/PhRMA
www.Twitter.com/PhRMA

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with nearly 50 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and SUDEP, find a cure, and overcome the challenges created by epilepsy through efforts including education, advocacy, and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.

"Like" the Epilepsy Foundation on Facebook at www.Facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn.

Photo - http://photos.prnewswire.com/prnh/20150713/235611-INFO 
Photo - http://photos.prnewswire.com/prnh/20150713/235612-INFO
Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO


 


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. PhRMA Launches "Im Not Average" Campaign to Highlight the Stories of Cancer Survivors
2. PhRMA Foundation Launches New Web Platform to Support Researchers in Developing Life-Saving, Cost-Effective Medicines
3. Week in Review: The Latest from PhRMA
4. PhRMA Foundation Announces New Young Investigator Grantees to Advance Medication Adherence Research
5. Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman
6. PhRMA Applauds 2015 We Work For Health Champion Award Winners
7. PhRMA Member Companies Invested $51.2 Billion in R&D in 2014
8. National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity
9. PhRMA Elects New Members of Board of Directors
10. UCB and IBM Collaborate to Personalize Care for Epilepsy Patients
11. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon ... ... CS100i ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  ... This field correction also applies to any System 98 ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is PTSD Awareness Day. ... than 20% will receive adequate care due to lack of effective treatments, fear of ... at all. And left untreated, veterans are at an increased risk for self-destructive behavior, ...
(Date:6/26/2017)... ... 2017 , ... Antoine Dental Center is now offering various types of dental implants ... as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is ... sturdy, lasting new root for the tooth. , Several types of dental implants are ...
Breaking Medicine News(10 mins):